BOSTON, December 19, 2024--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from its Phase 2 study of suzetrigine in people with painful ...

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...

This page lists all known medications that could potentially lead to 'Lumbar radiculopathy' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

BOSTON-- (BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...

PALM SPRINGS, California — A new sodium channel blocker, CNV1014802, reduces neuropathic pain from lumbosacral radiculopathy, a phase 2 trial shows. Patients taking the drug improved by about 1 point ...

CNV1014802 showed a statistically significant reduction in pain Well tolerated and effective therapeutic dose without any requirement for dose titration Performance potentially broadens the use in ...

The study was performed as part of a multicentre randomised controlled trial on the treatment effect of caudal epidural injections. [19] Eligible patients with suspected chronic lumbar radiculopathy, ...

Objective: To determine the presence of intraforaminal synovial cysts resulting in nerve root compression. Methods: A 26 year old man presenting with left leg pain was admitted. He had no motor, ...